Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Prime Editing has potential to be best-in-class approach for AATD ---- Previously undisclosed program now emerging from within liver platform; ...
The Scientist5y
Avacta Group plc TMAC programme accelerates: clinical trial planned for early 2020
Avacta Group plc (AIM: AVCT), the developer of Affimer ® biotherapeutics and research reagents, announces that it is planning to submit an IND/CTA application early in 2020 to test the TMAC™ linker in ...
Yahoo Finance6d
Prime Medicine, Inc. (PRME)
expect to file IND and/or CTA in 1H 2026 -- -- Additional high-value programs advancing through preclinical development -- CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Prime Medicine ...
abc2721d
Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 and the preclinical pipeline
RVU120: emphasis on rapid study enrollment and quality data generation in 2025 RVU305: IND/CTA-enabling studies are ongoing and planned to be completed in H2 2025. Preclinical discovery and ...